This is a StreetInsider.com Premium Only Page

MEI Pharma (MEIP) – Company Press Releases

Apr 11, 2024 08:02 AM MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

Apr 11, 2024 08:00 AM MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

Apr 10, 2024 08:00 AM MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Mar 26, 2024 08:00 AM MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Feb 13, 2024 05:05 PM MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

Jan 16, 2024 05:00 PM MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

Dec 11, 2023 12:00 PM MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

Nov 9, 2023 04:05 PM MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

Nov 8, 2023 08:00 AM MEI Pharma to Present at the Stifel 2023 Healthcare Conference

Nov 6, 2023 04:57 PM MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock

Nov 2, 2023 09:00 AM MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

Nov 1, 2023 09:00 AM MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital

Oct 17, 2023 05:33 PM MEI Pharma Recommends Stockholders Not to Consent

Oct 2, 2023 06:00 AM MEI Pharma Adopts Limited-Duration Stockholder Rights Plan

Sep 28, 2023 05:00 PM MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions

Sep 26, 2023 04:02 PM MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights

Sep 21, 2023 08:00 AM MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023

Sep 18, 2023 08:00 AM MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car

Aug 16, 2023 08:00 AM MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer

Jul 23, 2023 02:30 PM MEI Pharma Announces Results of Special Meeting of Stockholders

Jul 19, 2023 08:00 AM MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

Jul 18, 2023 09:00 AM MEI Pharma Responds to Anson and Cable Car

Jul 17, 2023 09:17 AM Anson and Cable Car File Preliminary Consent Materials to Remove Entire Board of Directors at MEI Pharma, Inc.

Jul 17, 2023 08:00 AM MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction

Jul 13, 2023 04:05 PM MEI Pharma Postpones Special Meeting of Shareholders

Jul 11, 2023 08:00 AM MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals

Jul 7, 2023 08:00 AM MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals

Jul 5, 2023 08:30 AM ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.

Jul 5, 2023 08:00 AM MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals

Jun 29, 2023 08:00 AM MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals

Jun 27, 2023 05:15 PM MEI Pharma Responds to Anson and Cable Car

Jun 15, 2023 12:08 PM MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

Jun 15, 2023 08:00 AM MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

Jun 13, 2023 08:00 AM MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

Jun 2, 2023 08:00 AM MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor

Jun 1, 2023 04:22 PM Anson Funds and Cable Car Capital Issue Statement Regarding MEI Pharma’s Rejection of Their Acquisition Proposal

Jun 1, 2023 08:00 AM MEI Pharma Board of Directors Rejects Unsolicited Proposal

May 30, 2023 05:40 PM MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal

May 23, 2023 08:00 AM MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

May 11, 2023 04:05 PM MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights

Apr 14, 2023 04:15 PM MEI Pharma Announces 1-for-20 Reverse Stock Split

Feb 23, 2023 07:00 AM MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates

Feb 9, 2023 04:05 PM MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights

Dec 6, 2022 04:00 PM MEI Pharma Announces Adjournment of Annual Meeting of Stockholders

Dec 5, 2022 05:01 PM MEI Pharma Initiates Strategic Realignment

Dec 5, 2022 05:00 PM MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting

Nov 18, 2022 08:00 AM Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan

Nov 14, 2022 04:05 PM MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights

Nov 3, 2022 09:00 AM MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022

Oct 3, 2022 04:00 PM MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)